AVEO Pharmaceuticals, Inc. AVEO
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 521.45M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 42.86
- Beta
- 0.98
- Short ratio
- 2.00
- Inst. own
- 34.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 13, 2023
- 50-d avg
- 14.90
- 200-d avg
- 9.19
- 1y target
- 15.00
News
3 months ago businesswire.com
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for…
4 months ago reuters.com
Natera, Aveta partner on late-stage head and neck cancer trial
Genetic testing firm Natera and cancer drug developer Aveta Biomics said on Monday they have partnered on a late-stage study of an experimental therapy for head and neck cancer, in a bid to improve…
2 years ago globenewswire.com
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer –
2 years ago globenewswire.com
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer –
2 years ago globenewswire.com
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist
BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology , an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall…
2 years ago globenewswire.com
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized,…
3 years ago zacks.com
4 Drug Stocks That More Than Doubled This Year
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.
3 years ago zacks.com
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?
Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.
3 years ago zacks.com
AVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate Revisions
AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
3 years ago zacks.com
What Makes AVEO Pharmaceuticals (AVEO) a Strong Momentum Stock: Buy Now?
Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 years ago zacks.com
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
3 years ago zacks.com
AVEO Pharmaceuticals (AVEO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 years ago zacks.com
AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?
AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.
4 years ago zacks.com
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?
Here is how AVEO Pharmaceuticals (AVEO) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
4 years ago pulse2.com
Why LG Chem Is Buying AVEO Oncology (AVEO) For $566 Million
LG Chem is buying AVEO Oncology for $566 million. These are the details.
4 years ago schaeffersresearch.com
Biopharma Stock Soaring on Buyout News
Aveo Pharmaceuticals Inc (NASDAQ:AVEO) stock is soaring today, up 40.7% at $14.74 at last glance, after news that South Korean chemical company LG Chem plans to buy the biopharmaceutical name for $15…
4 years ago investors.com
Aveo Stock Continues Its Bullish Run After Snagging $566 Million LG Chem Buyout
Aveo Oncology agreed to be acquired by Korea's LG Chem on Tuesday, and Aveo stock skyrocketed to a near two-year high on the news. The post Aveo Stock Continues Its Bullish Run After Snagging $566…
4 years ago investorplace.com
What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today?
AVEO Oncology (NASDAQ: AVEO ) stock jumped 40% in premarket trading after LG Chem (OTCMKTS:LGCLF) said it would buy the company for $15/share in cash. The price implies a value of $566 million for…
4 years ago zacks.com
3 Breakout Stocks to Keep an Eye on for Solid Returns
Par Pacific (PARR), AVEO Pharmaceuticals (AVEO) and Heritage Commerce Corp (HTBK) have been selected as the breakout stocks for today.
4 years ago zacks.com
Is AVEO Pharmaceuticals (AVEO) Stock Outpacing Its Medical Peers This Year?
Here is how AVEO Pharmaceuticals (AVEO) and Trevi Therapeutics, Inc. (TRVI) have performed compared to their sector so far this year.
-
4 years ago benzinga.com
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
-
4 years ago benzinga.com
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
-
4 years ago benzinga.com
68 Biggest Movers From Yesterday
Gainers Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie Talkie in Microsoft…
-
4 years ago benzinga.com
96 Biggest Movers From Yesterday
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning trading, 400 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
-
5 years ago benzinga.com
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
-
5 years ago benzinga.com
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report earnings for its first quarter.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
On Thursday morning, 420 companies hit new 52-week highs.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 118 companies set new 52-week highs.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Stocks That Hit 52-Week Lows On Friday
-
7 years ago benzinga.com
60 Stocks Moving In Tuesday's Mid-Day Session
60 Stocks Moving In Tuesday's Mid-Day Session
-
12 years ago benzinga.com
Earnings Scheduled For March 13, 2014
Earnings Scheduled For March 13, 2014